Cargando…

MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators

ABSTRACT: A severe lack of early diagnosis coupled with resistance to most available therapeutic options renders pancreatic cancer as a major clinical concern. The limited efficacy of current treatments necessitates the development of novel therapeutic strategies that are based on an understanding o...

Descripción completa

Detalles Bibliográficos
Autores principales: Daoud, Afra Z., Mulholland, Eoghan J., Cole, Grace, McCarthy, Helen O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868851/
https://www.ncbi.nlm.nih.gov/pubmed/31752758
http://dx.doi.org/10.1186/s12885-019-6284-y
_version_ 1783472358660505600
author Daoud, Afra Z.
Mulholland, Eoghan J.
Cole, Grace
McCarthy, Helen O.
author_facet Daoud, Afra Z.
Mulholland, Eoghan J.
Cole, Grace
McCarthy, Helen O.
author_sort Daoud, Afra Z.
collection PubMed
description ABSTRACT: A severe lack of early diagnosis coupled with resistance to most available therapeutic options renders pancreatic cancer as a major clinical concern. The limited efficacy of current treatments necessitates the development of novel therapeutic strategies that are based on an understanding of the molecular mechanisms involved in pancreatic cancer progression. MicroRNAs (miRNAs) are non-coding small RNAs that regulate the expression of multiple proteins in the post-translation process and thus have promise as biomarkers, prognostic agents, and as advanced pancreatic therapies. Profiling of deregulated miRNAs in pancreatic cancer can correlate to diagnosis, indicate optimal treatment and predict response to therapy. Furthermore, understanding the main effector genes in pancreatic cancer along with downstream pathways can identify possible miRNAs as therapeutic candidates. Additionally, obstacles to the translation of miRNAs into the clinic are also considered. Distinct miRNA expression profiles can correlate to stages of malignant pancreatic disease, and hold potential as biomarkers, prognostic markers and clinical targets. However, a limited understanding and validation of the specific role of such miRNAs stunts clinical application. Target prediction using algorithms provides a wide range of possible targets, but these miRNAs still require validation through pre-clinical studies to determine the knock-on genetic effects. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-6868851
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68688512019-12-12 MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators Daoud, Afra Z. Mulholland, Eoghan J. Cole, Grace McCarthy, Helen O. BMC Cancer Debate ABSTRACT: A severe lack of early diagnosis coupled with resistance to most available therapeutic options renders pancreatic cancer as a major clinical concern. The limited efficacy of current treatments necessitates the development of novel therapeutic strategies that are based on an understanding of the molecular mechanisms involved in pancreatic cancer progression. MicroRNAs (miRNAs) are non-coding small RNAs that regulate the expression of multiple proteins in the post-translation process and thus have promise as biomarkers, prognostic agents, and as advanced pancreatic therapies. Profiling of deregulated miRNAs in pancreatic cancer can correlate to diagnosis, indicate optimal treatment and predict response to therapy. Furthermore, understanding the main effector genes in pancreatic cancer along with downstream pathways can identify possible miRNAs as therapeutic candidates. Additionally, obstacles to the translation of miRNAs into the clinic are also considered. Distinct miRNA expression profiles can correlate to stages of malignant pancreatic disease, and hold potential as biomarkers, prognostic markers and clinical targets. However, a limited understanding and validation of the specific role of such miRNAs stunts clinical application. Target prediction using algorithms provides a wide range of possible targets, but these miRNAs still require validation through pre-clinical studies to determine the knock-on genetic effects. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2019-11-21 /pmc/articles/PMC6868851/ /pubmed/31752758 http://dx.doi.org/10.1186/s12885-019-6284-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Debate
Daoud, Afra Z.
Mulholland, Eoghan J.
Cole, Grace
McCarthy, Helen O.
MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators
title MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators
title_full MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators
title_fullStr MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators
title_full_unstemmed MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators
title_short MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators
title_sort micrornas in pancreatic cancer: biomarkers, prognostic, and therapeutic modulators
topic Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868851/
https://www.ncbi.nlm.nih.gov/pubmed/31752758
http://dx.doi.org/10.1186/s12885-019-6284-y
work_keys_str_mv AT daoudafraz micrornasinpancreaticcancerbiomarkersprognosticandtherapeuticmodulators
AT mulhollandeoghanj micrornasinpancreaticcancerbiomarkersprognosticandtherapeuticmodulators
AT colegrace micrornasinpancreaticcancerbiomarkersprognosticandtherapeuticmodulators
AT mccarthyheleno micrornasinpancreaticcancerbiomarkersprognosticandtherapeuticmodulators